Titration of nocturnal oxygen needs to prevent desaturations for Sleep Apnea, Central

Phase-Based Progress Estimates
3
Effectiveness
3
Safety
Sleep Apnea, Central+4 More
Titration of nocturnal oxygen needs to prevent desaturations - Device
Eligibility
18+
All Sexes
What conditions do you have?
Select

Study Summary

This trial is testing different levels of oxygen flow during sleep in order to minimize oxygen desaturation while also minimizing periods of hyperoxia.

Eligible Conditions
  • Sleep Apnea, Central
  • Congestive heart failure

Treatment Effectiveness

Effectiveness Progress

3 of 3
This is further along than 93% of similar trials

Study Objectives

2 Primary · 0 Secondary · Reporting Duration: Three months ( titration completed 3 times during the study period)

Three months ( titration completed 3 times during the study period)
Changes in optimal levels of O2 flow ( EO2F) which prevent nocturnal O2 desaturation
Three months (new titration sessions completed 3 times during the study period)
Accuracy of automated oxygen titration

Trial Safety

Safety Progress

3 of 3
This is further along than 85% of similar trials

Trial Design

1 Treatment Group

Oxygen therapy
1 of 1
Experimental Treatment

14 Total Participants · 1 Treatment Group

Primary Treatment: Titration of nocturnal oxygen needs to prevent desaturations · No Placebo Group · Phase 4

Oxygen therapy
Device
Experimental Group · 1 Intervention: Titration of nocturnal oxygen needs to prevent desaturations · Intervention Types: Device

Trial Logistics

Trial Timeline

Approximate Timeline
Screening: ~3 weeks
Treatment: Varies
Reporting: three months ( titration completed 3 times during the study period)

Who is running the clinical trial?

Laval UniversityLead Sponsor
385 Previous Clinical Trials
164,365 Total Patients Enrolled
Philips RespironicsIndustry Sponsor
65 Previous Clinical Trials
9,668 Total Patients Enrolled
7 Trials studying Sleep Apnea, Central
1,905 Patients Enrolled for Sleep Apnea, Central
OxynovUNKNOWN

Eligibility Criteria

Age 18+ · All Participants · 3 Total Inclusion Criteria

Mark “yes” if the following statements are true for you:

About The Reviewer

Michael Gill preview

Michael Gill - B. Sc.

First Published: October 22nd, 2021

Last Reviewed: October 27th, 2022

Michael Gill holds a Bachelors of Science in Integrated Science and Mathematics from McMaster University. During his degree he devoted considerable time modeling the pharmacodynamics of promising drug candidates. Since then, he has leveraged this knowledge of the investigational new drug ecosystem to help his father navigate clinical trials for multiple myeloma, an experience which prompted him to co-found Power Life Sciences: a company that helps patients access randomized controlled trials.